7 known cases. View patent page →
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.
Celgene Corp. and Children's Medical Center Corp. sued Barr Laboratories over thalidomide ANDA; the '784 patent was among the patents-in-suit. The case was dismissed after Barr withdrew its ANDA, with Barr's antitrust counterclaims dismissed with prejudice and patent claims dismissed without prejudice.
Action identified as one of six district-court actions relating to the '501 patent, consolidated with the Barr actions and dismissed without prejudice on May 21, 2010. Whether the '018 patent was separately asserted in this action is unconfirmed.
Consolidated purchaser/insurer antitrust litigation alleging Celgene improperly listed Thalomid/Revlimid distribution-method patents in the Orange Book and pursued sham litigation. The '018 patent is referenced within the distribution-method patent family but is not asserted for infringement.
Celgene asserted US 6,561,976 as an asserted 'Celgene Patent' in an ANDA/Hatch-Waxman suit against Natco and others over generic THALOMID/REVLIMID. A May 7, 2014 stipulation recorded Natco's non-contest of infringement of certain claims of the ’976 patent. The case settled, and the docket terminated on Jan. 5, 2016.
Celgene sued Lannett in an ANDA/Hatch-Waxman case over generic THALOMID; Lannett counterclaimed for monopolization/sham litigation. Google Patents lists US 6,561,976 as involved. Settled.
Flagged on the Google Patents litigation panel for US 6,561,976; defendant(s) and disposition could not be confirmed, but narrative describes it as almost certainly another 2007 THALOMID/thalidomide ANDA suit.